Botulinum neurotoxin (BoNT) treatment in functional movement disorders: long-term follow-up, 2020, Dreissen et al

Andy · Jul 16, 2020

We recently reported on a randomised controlled trial (RCT) assessing the effect of botulinum neurotoxin (BoNT) in 48 patients with chronic (>1 year) jerky and tremulous functional movement disorders (FMD).1 The RCT showed an improvement of motor symptoms in both treatment arms (16/25, 64% BoNT vs 13/23, 57% placebo). The proportion of improved patients increased to 81% (35/43) at the end of the open-label phase. Despite symptom improvement, there was no change in quality of life and disability. In the present study, our aim was to assess the long-term outcome of this study population.
Click to expand...

Open access, https://jnnp.bmj.com/content/early/2020/07/12/jnnp-2020-323684

Log in or Sign up

Botulinum neurotoxin (BoNT) treatment in functional movement disorders: long-term follow-up, 2020, Dreissen et al

Andy Committee Member

Share This Page

Log in or Sign up

Botulinum neurotoxin (BoNT) treatment in functional movement disorders: long-term follow-up, 2020, Dreissen et al

Andy Committee Member

Share This Page

Useful Searches